S 16317 is an orally active dihydropyridine derivative with low calcium channel affinity (Ki: 0.55 μM). S 16317 inhibits P-gp mediated efflux of ADR. S 16317 overcomes multidrug resistance in tumor.

Mm-C3-OSu (Methyl Maleate-C3-N-Hydroxysuccinimide Ester) is a structurally defined linker intermediate with a cis-configured methyl maleate (Mm) core and a C3 alkyl chain terminated by an N-hydroxysuccinimide (OSu) reactive group, designed for constructing stable antibody-drug conjugates (ADCs).

Z1609609733 (Compound 18) is a non-covalent 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 1.46 μM. Z1609609733 significantly inhibits serine synthesis and cancer metabolism with complete abrogation of cell proliferation.

308-R-C4-PEG3-C1-Boc is a SGK3 ligand-linker conjugate that can be used for synthesis of PROTAC SGK3 degrader-2.

USP7 Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for USP7 and a PROTAC linker, which recruits E3 ligases. USP7 Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC USP7 Degrader-1.

LCB 2853 (sodium) is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 (sodium) exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 (sodium) can be used for the research of cardiovascular disease, such as hypertension.

RBx-7796 (sodium) is a competitive, highly selective, orally active 5-LO (IC50 = 3.5 mM for human 5-LO enzyme) inhibitor. RBx-7796 (sodium) can effectively inhibit 5-LO activity and LTB4 release. RBx-7796 (sodium) can significantly inhibit airway inflammation and bronchial constriction.

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia.

PD 155080 is a selective endothelin A receptor (ETA receptor) antagonist. PD 155080 reduces coronary resistance in the isolated rat heart model. PD 155080 improves myocardial systolic function and diastolic function in the ischemia/reperfusion model. PD 155080 can be used for the study of cardiovascular diseases.

Yoda2 (KC289) is the potassium salt of Yoda1. Yoda2 is an agonist of PIEZO1 with an EC50 of 150 nM. Yoda2 evokes Ca2+ elevation in HeLa cells. Yoda2 can cause concentration-dependent and NO-dependent relaxation in mouse portal vein (EC50 = 1.2 μM). Yoda2 can stimulate NOS3 and NO production.

E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.

CKD-731 is a Fumagillin analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer.

UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC50 = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice.

ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock.

ent-Rhizocarpic acid is an enantiomer of Rhizocarpic acid. ent-Rhizocarpic acid has more potent antibacterial and antiparasitic activity against Staphylococcus aureus (ATCC 25923) and Giardiaduodenalis 713 compared to Rhizocarpic acid. ent-Rhizocarpic acid also has a weak but selective antitumor activity against NS-1 cells.

L-163007 is an orally active AT1/2 receptor antagonist. L-163007 can be used for the research of cardiovascular disease, such as hypertension.

OSBP ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for OSBP and a PROTAC linker, which recruits E3 ligases. OSBP ligand-Linker Conjugate 1 can be used for synthesis of PROTAC OSBP Degrader-1.

CP-114271 is a potent selective β3-adrenergic receptor agonist. CP-114271 possesses an in vivo efficacy in rodent models. CP-114271 can be used for obesity research.

RIPK1-ligand-2 is a RIPK1 inhibitor. RIPK1-ligand-2 can be used for synthesis of PROTAC RIPK1 Degrader-1.

AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases.

N-Descyclopropanecarbaldehyde Olaparib suberic acid is a ligand-linker conjugate that can be used for the synthesis of DDO3602.

CP-664511 is an orally active and potent α4β1 integrin antagonist with anti-inflammatory effects (IC50=0.52 nM). CP-664511 inhibits the interaction between α4β1 and vascular cell adhesion molecule-1 (VCAM-1), significantly reducing eosinophil infiltration into lung tissue. CP-664511 is promising for research of asthma and allergic airway diseases.

CP-331684 is an orally active agonist of β3-Adrenergic receptor. CP-331684 can be studied in research on obesity.

AM-461 is a DP2 receptor (Prostaglandin Receptor) antagonist. AM-461 can be used for the researches of inflammation and immunology, such as asthma.

PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. The [18F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer.

CB 3705 is a dihydrofolate reductase (DHFR) and thymidylate synthetase (TS) inhibitor. CB 3705 inhibits L1210 cells and mutant L1210 cell line (L1210:C15) with ID50s of 4.77 μM and 408 μM, respectively.

EMD527040 (hydrochloride) is a highly potent and selective αvβ6 antagonist with anti-fibrotic activity. EMD527040 (hydrochloride) is used in the research of liver cancer and liver fibrosis.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

APL-5125 (Compound 61f) is a potent, selective and orally active ATP-competitive CK2α inhibitor with an IC50 of 0.348 nM and a Ki of 0.095 nM. APL-5125 binds to CK2α in a bivalent manner, simultaneously interacting with the ATP-binding site and the αD pocket. APL-5125 exhibits antitumor activity and can be used for the research of cancer, such as colon cancer.

GA-0056 is an angiotensin II receptor blocker. GA-0056 can be used in the research of heart disease.